Scroll To Top
Health

FDA approves once-daily Zerit


Support The Advocate
LGBTQ+ stories are more important than ever. Join us in fighting for our future. Support our journalism.

The Food and Drug Administration on Tuesday approved a new, extended-release form of the HIV nucleoside reverse transcriptase inhibitor Zerit (d4T), which will be marketed as Zerit XR by drugmaker Bristol-Myers Squibb. The new formulation can be taken just once a day. Data from clinical trials of the medication show that it is as effective as the standard twice-daily dosing of d4T and that reducing the pill burden may help people with HIV better stick to their anti-HIV drug regimens.

Recommended Stories for You

LGBTQ Task ForceOut / Advocate Magazine - Jonathan Groff & Wayne Brady

From our Sponsors

Most Popular

Latest Stories